ReviewEuropean journal of clinical pharmacology2009
Clinical pharmacokinetics of aminoglycosides in the neonate: a review.
Review in European journal of clinical pharmacology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 2 syntheses or guidelines pooled it, 91 citations in OpenAlex.
- One dose per day compared to multiple doses per day of gentamicin for treatment of suspected or proven sepsis in neonates.The Cochrane database of systematic reviews · 2016Pooled it
- Development and Evaluation of a Gentamicin Pharmacokinetic Model That Facilitates Opportunistic Gentamicin Therapeutic Drug Monitoring in Neonates and Infants.Antimicrobial agents and chemotherapy · 2016Pooled it
- Evaluating renal function and age as predictors of amikacin clearance in neonates: model-based analysis and optimal dosing strategies.British journal of clinical pharmacology · 2016Trial
- Impact of kidney maturation on aminoglycoside exposure in term-born pediatric patients: an in silico study.Pediatric nephrology (Berlin, Germany) · 2026Article
- One Model to Dose Them All: A Population Pharmacokinetic Model for Multiple Aminoglycosides Across the Human Lifespan.Journal of clinical pharmacology · 2026Article
- Amikacin pharmacokinetics, target attainment, and predictors in critically ill children: a retrospective cohort.European journal of pediatrics · 2026Article
- Physiology-Based Pharmacokinetic Modeling for Prediction of Gentamicin Plasma Profile in Dogs with Renal Dysfunction.Pharmaceutics · 2026Article
- A Review of Vancomycin, Gentamicin, and Amikacin Population Pharmacokinetic Models in Neonates and Infants.Clinical pharmacokinetics · 2025Review
- Factors associated with elevated gentamicin trough levels in neonates: a retrospective analysis of dosing and clinical parameters.Frontiers in pediatrics · 2025Article
- Pharmacokinetic and Pharmacodynamic Considerations of Antibiotic Use in Neonates.Antibiotics (Basel, Switzerland) · 2023Review
- Evaluating and Improving Neonatal Gentamicin Pharmacokinetic Models Using Aggregated Routine Clinical Care Data.Pharmaceutics · 2022Article
- Use of Antibiotics in Preterm Newborns.Antibiotics (Basel, Switzerland) · 2022Review
- Therapeutic drug monitoring of amikacin: quantification in plasma by liquid chromatography-tandem mass spectrometry and work experience of clinical pharmacists.European journal of hospital pharmacy : science and practice · 2022Article
- Extended Interval Aminoglycoside Treatment forThe journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2022Article
- Therapeutic Drug Monitoring Is a Feasible Tool to Personalize Drug Administration in Neonates Using New Techniques: An Overview on the Pharmacokinetics and Pharmacodynamics in Neonatal Age.International journal of molecular sciences · 2020Review
- Population pharmacokinetics and pharmacodynamics of dobutamine in neonates on the first days of life.British journal of clinical pharmacology · 2020Article
- ORC-13661 protects sensory hair cells from aminoglycoside and cisplatin ototoxicity.JCI insight · 2019Article
- Individualization of treatment with gentamicin in neonates based on drug concentration in the blood serum.Developmental period medicine · 2019Article
- Population Pharmacokinetics and Dosing Considerations for Gentamicin in Newborns with Suspected or Proven Sepsis Caused by Gram-Negative Bacteria.Antimicrobial agents and chemotherapy · 2017Article
- Should gentamicin trough levels be routinely obtained in term neonates?Journal of perinatology : official journal of the California Perinatal Association · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSepsis is common in neonates and is a major cause of morbidity and mortality. Sixty percent of preterm neonates receive at least one antibiotic, and 43% of the antibiotics administered to these neonates are aminoglycosides. The clearance (Cl), serum half-life (t(1/2)), and volume of distribution (Vd) of aminoglycosides change during the neonatal life, and the pharmacokinetics of aminoglycosides need to be studied in neonates in order to optimise therapy with these drugs.
objectiveThe aim of this work is to review the published data on the pharmacokinetics of aminoglycosides in order to provide a critical analysis of the literature that can be a useful tool in the hands of physicians.
methodsThe bibliographic search was performed electronically using PubMed, as the search engine, through July 11th, 2008. Firstly, a Medline search was performed with the keywords "pharmacokinetics of aminoglycosides in neonates" with the limit of "human". Other Medline searches were performed with the keywords "pharmacokinetics of ... in neonates" followed by the name of the aminoglycosides: amikacin, gentamicin, netilmicin and tobramycin. In addition, the book Neofax: A Manual of Drugs Used in Neonatal Care by Young and Mangum (Thomson Healthcare, 2007) was consulted.
resultsThe aminoglycosides are mainly eliminated by the kidney, and their elimination rates are reduced at birth. As a consequence Cl is reduced and t(1/2) is prolonged in the neonate as compared to more mature infants. The high body-water content of the neonate results in a large Vd of aminoglycosides as these drugs are fairly water soluble. Postnatal development is an important factor in the maturation of the neonate, and as postnatal age proceeds, Cl of aminoglycosides increases.
conclusionThe maturation of the kidney governs the pharmacokinetics of aminoglycosides in the infant. Cl and t(1/2) are influenced by development, and this must be taken into consideration when planning a dosage regimen with aminoglycosides in the neonate. Aminoglycosides are fairly water soluble, and the larger water content of neonates yields a larger Vd in these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.